All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @heyshantaqtv on TikTok · 59s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @heyshantaqtv's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00You have a zimppack face.
  2. 0:01Of course I do.
  3. 0:02I've lost a lot of weight in a short amount of time,
  4. 0:05and I lost some volume.
  5. 0:06But listen, I'm contouring my face.
  6. 0:10I got the right tools.
  7. 0:11Yes, this is from MediCUBE, y'all.
  8. 0:13When I'm talking about reducing my smile lines,
  9. 0:16contouring my face, I use this thing
  10. 0:19about two to three minutes, three times a day, y'all.
  11. 0:24And y'all the ones asking me what I've been doing
  12. 0:27to my skin because y'all been noticing.
  13. 0:29I use MediCUBE, I use a whole plethora of other products.
  14. 0:36And I was using this one first.
  15. 0:39This is the first MediCUBE, and I upgraded it y'all.
  16. 0:41Now this thing, it was 350, but it's 290, 299.
  17. 0:46But if you want good skin, you won't have to pay for it.
  18. 0:51Okay?
  19. 0:52And these products are good.
  20. 0:53Korean products is where it's at y'all.
  21. 0:56Scientific and proven.

ShantaQ's beauty hack claim needs context we don't have

ShantaQuilette

TikTok creator

163.6K viewsWatch on TikTok →

Quick answer

GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media. Microcurrent home devices have limited but real evidence for improving superficial skin tone and muscle firmness, though they do not address the subcutaneous fat redistribution that drives GLP-1-related facial changes. Patients concerned about facial volume loss while on GLP-1 therapy should discuss the rate of weight loss, protein intake, and potential dermatologic interventions with their prescriber.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For ShantaQ's beauty hack claim needs context we don't have, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

ShantaQ's beauty hack claim needs context we don't have should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "ShantaQ's beauty hack claim needs context we don't have" from ShantaQuilette. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media.

The reason this review is not generic is the source wording and the canonical claim label "glp1 listen try it a money back guarantee beauty beautyhacks." In this clip, the useful excerpt is: "You have a zimppack face." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media. Microcurrent home devices have limited but real evidence for improving superficial skin tone and muscle firmness, though they do not address the subcutaneous fat redistribution that drives GLP-1-related facial changes. Patients concerned about facial volume loss while on GLP-1 therapy should discuss the rate of weight loss, protein intake, and potential dermatologic interventions with their prescriber.
  • GLP-1-related facial volume loss is real: rapid weight loss reduces subcutaneous facial fat, which is distinct from skin aging and requires different interventions than topical or device-based skincare.
  • Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al., 2019), but home devices deliver lower current than clinical studies used, so results are likely more modest.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GLP-1-related facial volume loss is real: rapid weight loss reduces subcutaneous facial fat, which is distinct from skin aging and requires different interventions than topical or device-based skincare.
  • Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al., 2019), but home devices deliver lower current than clinical studies used, so results are likely more modest.
  • Jacobs et al. (2023) found that the faster the weight loss, the more pronounced the facial aging markers, suggesting that slowing loss rate with your prescriber may reduce the effect.
  • She used at least two MediCUBE devices plus 'a whole plethora of other products,' meaning any observed skin improvement cannot be attributed to one product with confidence.
  • No topical product or consumer microcurrent device restores subcutaneous fat volume. For significant volume loss, injectable fillers remain the only intervention with strong clinical evidence.
  • The $299 price point for a home microcurrent device is within the range sold by legitimate brands, but the FDA does not independently verify efficacy claims for most at-home beauty devices before sale.
  • If you are on semaglutide or tirzepatide and concerned about facial changes, ask your prescriber about adjusting your rate of loss and consult a board-certified dermatologist before investing in device-based solutions.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @heyshantaqtv actually say?

She acknowledged her own facial volume loss directly: "I have a Ozempic face. Of course I do. I've lost a lot of weight in a short amount of time." She then credited a MediCUBE device, used "two to three minutes, three times a day," with reducing smile lines and contouring her face. She called Korean skincare products "scientific and proven" and implied the $299 device is worth it for "good skin." To her credit, she wasn't claiming the device reverses GLP-1-related fat loss. She was claiming it helps contour and improve skin appearance after that loss, which is a more modest claim than most beauty influencers make. That distinction matters here.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ShantaQuilette · TikTok creator

163.6K views on this video

Listen, try it a money back guarantee. #beauty #beautyhacks #beaitymode #beatytips

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1-related facial volume loss?

GLP-1-related facial volume loss is real: rapid weight loss reduces subcutaneous facial fat, which is distinct from skin aging and requires different interventions than topical or device-based skincare.

What does the video say about microcurrent devices have peer-reviewed support for mild skin tightening (franks?

Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al., 2019), but home devices deliver lower current than clinical studies used, so results are likely more modest.

What does the video say about jacobs et al. (2023) found?

Jacobs et al. (2023) found that the faster the weight loss, the more pronounced the facial aging markers, suggesting that slowing loss rate with your prescriber may reduce the effect.

What does the video say about she used at least two medicube devices plus 'a whole?

She used at least two MediCUBE devices plus 'a whole plethora of other products,' meaning any observed skin improvement cannot be attributed to one product with confidence.

What does the video say about no topical product?

No topical product or consumer microcurrent device restores subcutaneous fat volume. For significant volume loss, injectable fillers remain the only intervention with strong clinical evidence.

What does the video say about the $299 price point for a home microcurrent device?

The $299 price point for a home microcurrent device is within the range sold by legitimate brands, but the FDA does not independently verify efficacy claims for most at-home beauty devices before sale.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ShantaQuilette, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.